Director Akkaraju Buys $10.7M of Alumis Stock After 55% Post-Trial Plunge
ALMS has more than doubled off its 52-week low of $3.76 on elevated volume (1.9× avg).
Summary
Director Srinivas Akkaraju bought $10.7M of Alumis stock after the lupus trial failure, offset by a $1.0M same-day sale that triggered short-swing profit disgorgement.
Key Events · Ownership and Investor Activity · ALMS
-
Director Buys $10.7M After Trial Miss
Srinivas Akkaraju purchased 986,721 shares for $10,726,255 across four transactions from September 4-8, 2026, at prices between $10.26 and $11.60, following the September 1 Phase 2b LUMUS trial miss that sent shares down 55%.
-
Concurrent $1.0M Sale
Akkaraju sold 96,131 shares for $1,014,028 on September 8 at $10.55, reducing the net purchase to approximately $9.7 million.
-
Section 16(b) Short-Swing Profit
The September 8 buys and sells were matchable under Section 16(b) for 48,066 shares (Samsara LP) and 48,065 shares (Samsara Opportunity Fund), and Akkaraju has agreed to disgorge the short-swing profit to the company.
-
Post-Transaction Holdings
Akkaraju's indirect holdings total 4,937,026 shares across Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., plus 3,553 shares held directly.
Analysis · ALMS · Life Sciences
Director Srinivas Akkaraju bought $10.7 million of Alumis stock across four transactions between September 4 and 8, just days after the company's Phase 2b LUMUS trial in lupus missed its primary endpoint and shares fell 55%. The purchase was made through two Samsara funds he controls, at prices between $10.26 and $11.60. He also sold $1.0 million of stock on September 8, and the filing discloses that some of the same-day buys and sells were matchable under Section 16(b), triggering short-swing profit liability that he has agreed to disgorge. The net effect is a $9.7 million increase in his economic exposure at a time when the market is questioning the company's lead asset.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALMS was trading at $9.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $3.76 to $31.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.